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ORIGINAL ARTICLE
Outpatient photodynamic-guided diagnosis of carcinoma in situ with flexible
cystoscopy: an alternative to conventional inpatient photodynamic-guided
bladder biopsies in the operating theatre?
Karin Mogensena, Anders Glenthøjb, Birgitte Grønkær Toftb, Thomas Scheikec and Gregers Gautier Hermanna
aDepartment of Urology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; bDepartment of Pathology,
Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark; cDepartment of Biostatistics, University of Copenhagen,
Copenhagen, Denmark
ABSTRACT
Objective: The aim of this prospective open comparative study was to establish whether conventional
photodynamic-guided bladder biopsies using general anaesthesia and rigid resectoscopes (inpatient)
can be replaced with less traumatic flexible cystoscopy in non-sedated patients (outpatient), without
compromising the diagnosis of carcinoma in situ (CIS).
Materials and methods: Thirty-one patients were included. After BCG instillation for CIS, bladder biop-
sies were obtained using photodynamic-guided flexible cystoscopy. Two weeks later, patients under-
went the conventional inpatient procedure. An external pathologist reviewed the biopsy samples. Pain
and quality of life (QoL) symptom score were recorded.
Results: Post-BCG biopsies showed only CIS in 10 patients; high-grade Ta or T1 tumour in three
patients, who were referred for cystectomy; and normal or low-grade tumour tissue in 18 patients.
There was a high agreement of identification of high-grade disease in biopsies and cytology using the
two methods (j¼ 0.93, 95% confidence interval 0.8–1.0). The outpatient procedure identified four
high-grade patients diagnosed as ‘normal/low-grade’ in the inpatient procedure. The opposite was
observed in two patients. Quality of biopsies did not differ between the two procedures. Pain scores
for outpatients were low, and median QoL symptom score was significantly lower than for inpatients
(24 vs 33, p¼ 0.02). Hospital length of stay was significantly longer for inpatients.
Conclusions: Outpatient photodynamic-guided flexible cystoscopy is less traumatic than the conven-
tional inpatient procedure in the diagnosis of CIS. It is safe and cost-effective, and may be an alterna-
tive to conventional inpatient biopsy procedures in patients with malignant urine cytology and normal
white-light cystoscopy.
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Carcinoma in situ (CIS) of the bladder is a flat, high-grade
non-invasive urothelial cancer, which, if left untreated, has a
high mortality rate [1,2]. Immunotherapy with instillation of
BCG is the recommended treatment [3]. European
Association of Urology (EAU) [4] and American Urological
Association (AUA) [5] guidelines stress the risk of disease pro-
gression in CIS, and the importance of biopsies to ensure a
correct diagnosis [5,6].
In accordance with both guidelines, fluorescence-guided
cystoscopy using photodynamic diagnosis (PDD, blue-light
cystoscopy) detects significantly more CIS lesions in the blad-
der than cystoscopy without fluorescence [7,8]. Therefore,
photodynamic-guided cystoscopy is recommended for diag-
nosis of CIS [4,5].
PDD is performed in an inpatient setting in the operating
theatre (OT), under general anaesthesia and with rigid 26 Fr
resectoscopes. New flexible 16 Fr cystoscopes for fluorescence
cystoscopy have recently been made available for outpatient
use where sedation is not required [9]. Biopsy techniques
have been developed for flexible cystoscopes that will provide
biopsies of sufficient quality for diagnosis of bladder tumour
stages as advanced as stage T1b and are routinely performed
in our outpatient department (OPD) [10]. Techniques are now
available for carrying out fluorescence-guided biopsies of the
bladder in the OPD with substantially less impact on the
patient than in the conventional inpatient procedure.
CIS mostly affects elderly patients, who are generally less
fit for surgery and general anaesthesia [11]. A less aggressive
outpatient diagnostic procedure for CIS as outlined in this
study may reduce patient morbidity and consume fewer
healthcare resources.
The aim of this study was to establish whether outpatient
photodynamic-guided flexible cystoscopy in awake
non-sedated outpatients could be an alternative to photo-
dynamic-guided biopsies taken in the OT using rigid cystos-
copy in anaesthetized patients without significantly
compromising the diagnosis of CIS, and whether this would
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be more acceptable to patients, while placing fewer
demands on the healthcare system.
Materials and methods
The study was a prospective open comparative study, with
the patients as their own control.
Approval was obtained from the Danish Ethical
Committee (H-4-2011-123) and the Danish Data Protection
Agency (2014-41-3109). The study was registered in ISRCTN
(ISRCTN48222814).
Patients
Patients were included if they had histologically confirmed pri-
mary or secondary CIS and had completed a course of six
weekly BCG treatments. The main exclusion criteria were
porphyria, macroscopic haematuria, fewer than six BCG treat-
ments, urinary tract infection and allergy to hexaminolevulinate
hydrochloride (HexvixVR ; Photocure ASA, Oslo, Norway). Previous
radiotherapy of the bladder was not an exclusion criterion.
From December 2012 to March 2016, 62 consecutive
patients commenced BCG treatments. Fifteen patients did
not fulfil the inclusion criteria and 16 patients did not want
to participate (two preferred general anaesthesia and 14
could not commit to regular hospital visits). Thirty-one
patients were included in the study. The median age was 72
years (range 48–89 years). The indication for BCG was only
CIS in 21 patients and concurrent CIS in 10 patients (CISþ Ta
high grade: nine patients; CISþ T1a high grade: one patient).
All 31 patients completed the study.
Written informed consent was obtained from all patients.
Outpatient procedure
Voided urine was collected in all patients before instilling
hexaminolevulinate, and sent for cytological analysis. One
hour before cystoscopy, 50ml hexaminolevulinate and 20ml
lidocaine were instilled into the bladder; all patients took 1 g
paracetamol and all but one patient took 600mg ibuprofen.
The patient was asked to empty the bladder after 1 h to
remove urine and thereby reduce green autofluorescence
from the urine during the PDD procedure.
Cystoscopy was performed in white and blue light using a
flexible 16 Fr PDD video cystoscope with a suction channel
(PDD 11272 VPI, D-Light C Light source; Karl Storz,
Tuttlingen, Germany). All suspicious lesions were recorded on
a bladder map and biopsies were taken with flexible biopsy
forceps (single-action jaws, 5 Fr, length 73 cm). No cauteriza-
tion of the biopsy areas was carried out.
Immediately after the OPD procedure, patients recorded
pain on a visual analogue scale (VAS) ranging from 0 to 10,
with 0 being no pain.
All data were blinded until after the following inpatient
procedure.
Inpatient procedure
Two weeks later, patients were hospitalized to undergo the
photodynamic-guided procedure repeated under general
anaesthesia. A xenon light source (D-light C systemVR ) fitted
with a light filter and a three-chip pendulum camera on a
26 Fr resectoscope, and a short-jaw biopsy forceps (Karl
Storz, Germany) were used in the OT. The OPD procedure
2 weeks earlier did not influence the inpatient procedure as
mucosal lesions from the biopsies had healed and could not
be identified. Two skilled urologists performed all of the pro-
cedures. No patient had the two cystoscopies carried out by
the same urologist.
All biopsies and urine samples were consecutively exam-
ined by the local pathologist, and after study completion
they were also examined by an external pathologist using
the WHO 2004 histological classification of urothelial carcin-
oma [12]. Urinary cytology was ranked as: ‘normal cells’,
‘atypical cells’ or ‘malignant cells’.
Quality of life assessment
The Quality of Life Questionnaire for Non-Muscle-Invasive
Bladder Cancer (QLQ NMIBC24; EORTC, Brussels, Belgium)
was completed by the patients after each procedure. This
questionnaire has been validated in a study measuring qual-
ity of life (QoL) after transurethral resection of bladder
tumours in the OT [13]. In that study, a score based on five
symptoms was calculated to assess lower urinary tract symp-
toms (LUTS) due to endoscopy.
Statistical analysis
The one-sample t test and Wilcoxon signed rank test were
used to test differences in patients’ symptoms caused by
the cystoscopy and biopsy procedure in the two settings.
These tests were conducted using the paired structure,
where each subject is his or her own control. The differen-
ces were approximately normally distributed when conduct-
ing t tests. For the comparison of the 2 by 2 diagnostic
tables, McNemar’s chi-squared test was used to test differ-
ences in the ability of the OT and OPD procedures to
diagnose CIS. This adjusts for the fact that there was a
paired comparison. To describe the extent to which the
OT and the OPD procedures give the same diagnosis, the
Cohen kappa coefficient (j) was calculated. The statistical
computing program R version 3.2.0 was used for all statis-




There was no significant difference between the procedures
regarding their ability to identify high-grade disease in biop-
sies (p¼ 0.68) (Table 1), and the concordance in the histo-
logical diagnosis between the two procedures showed a
Cohen j of 0.56 [95% confidence interval (CI) 0.25–0.86]. The
OPD procedure identified four high-grade patients who were
diagnosed as ‘normal’ or low-grade disease in the OT. The
opposite was observed in two patients (Table 1).
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In all but one patient with high-grade/CIS, malignant cells
were found in voided urine. No patients with low-grade dis-
ease had malignant cells in their urine. If these malignant
cells in the urine are considered to be diagnostic for high-
grade disease, even in patients where the biopsy indicates
low-grade disease or no disease, the agreement between the
diagnoses from OPD and OT becomes very high, giving simi-
lar results (p¼ 1.0; j¼ 0.93; 95% CI 0.8–1.0) (Table 2).
The number of biopsies taken, and the depth and quality
of biopsy for histopathological evaluation did not differ
between the two procedures (Table 3).
In 10 patients, histology showed only CIS; these patients
underwent a repeat BCG course. Three patients progressed
by developing exophytic high-grade Ta or T1 tumour, one
with concurrent CIS, and were referred for evaluation for rad-
ical cystectomy. Eighteen patients had normal biopsies or
low-grade tumour and entered maintenance BCG treatment.
Pain scores and QoL assessment
The median VAS score for pain experienced during the OPD
procedure was 1.5 (range 1–4).
All 31 QLQ-NMIBC24 questionnaires were returned after
the OPD procedure, and 29 after the OT procedure. The LUTS
score was significantly lower after the OPD procedure
(median 24, range 0–80) than after the OT procedure
(median 33, range 5–72, p¼ 0.02).
Length of procedure
Hospital length of stay was significantly longer for the OT
procedure. Median OT surgery time was 67min (range
39–96min); the surgery itself took a median of 20min (range
9–46min). Including the presurgery day, 21 patients were dis-
charged on the second day of hospitalization; eight were dis-
charged on day 3 and two on day 4. One patient was
readmitted because of urine retention after the procedure in
the OT with the rigid cystoscope. He stayed one night at the
hospital and was discharged with an indwelling urinary cath-
eter, which he retained for 8 days.
By contrast, the OPD procedure took a median of 17min
(range 10–26min). The entire procedure from arrival until dis-
charge lasted for about 2 h: 1 h for hexaminolevulinate instil-
lation and retention time and 1 h for the procedure, dressing
and so on. One patient had haematuria requiring an indwel-
ling catheter and bladder irrigation, with an additional one-
night stay.
Discussion
This study demonstrated that photodynamic-guided cystos-
copy using flexible cystoscopes may be an alternative to con-
ventional photodynamic-guided cystoscopy carried out in the
OT with general anaesthesia in the diagnosis of CIS.
Photodynamic-guided biopsy in the OPD is safe, well toler-
ated and associated with significantly fewer postprocedural
symptoms, compared to the procedure and biopsies
obtained in the OT.
Urinary cytology had a higher sensitivity for the diagnosis
of malignancy than did biopsy. The guidelines from the EAU
recommend that photodynamic-guided biopsies should be
considered following BCG treatment of CIS [4]. This study
suggests that biopsy may not be needed if urinary cytology
is negative. Urinary cytology could thus be used for primary
surveillance together with white-light cystoscopy using flex-
ible cystoscopes. If cytology contains cells that are suspicious
Table 2. Diagnosis of high-grade Ta/T1 or carcinoma in situ (CIS) lesions versus low-grade lesions or normal findings based on histological examination of biop-
sies and of urine cytology from the outpatient department and operating theatre after BCG treatment.
Operating theatre
Outpatient department Normal/low grade (n) High grade, CIS (n) Total
Normal/low grade (n) 18 1 19
High grade, CIS (n) 0 12 12 (12/13, 92%)
Total 18 13 (13/13, 100%) 31
Table 3. Characteristics of biopsies obtained through flexible cystoscopy in
the outpatient department (OPD) and through rigid endoscopes in the operat-
ing theatre (OT).
OPD OT
No. of biopsies per patient, mean (range) 3.9 (2–6) 4.5 (3–7)
Maximal size (mm) 2 2 2 7 2 2
Depth of biopsy
Lamina propria, superficial part 22 (18.5) 23 (17)
Lamina propria, deep part 76 (63) 88 (63)
Detrusor muscle 22 (18.5) 28 (20)
Total 120 (100) 139 (100)
Quality of biopsies for histopathological evaluation
Suitable for diagnosis 109 (90) 136 (97)
Less suitable for diagnosis 11 (9) 3 (2)
Not suitable for diagnosis 1 (1)a 2 (1)a
Total 121 141
Data are shown as n (%) unless otherwise indicated.
aNo urothelium, ulcus.
Table 1. Diagnosis of high-grade Ta/T1 or carcinoma in situ (CIS) lesions versus low-grade or normal findings based on histological examination of biopsies from
the outpatient department and operating theatre after BCG treatment (results of urine cytology not included).
Operating theatre
Outpatient department Normal/low grade (n) High grade, CIS (n) Total
Normal/low grade (n) 18 2 20
High grade, CIS (n) 4 7 11 (11/13, 85%)
Total 22 9 (9/13, 69%) 31
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for malignancy, photodynamic-guided biopsies can be carried
out with flexible cystoscopes in the OPD. Admission for
inpatient inspection may be avoided, along with stressful
procedures for the patients, while sparing health system
resources.
Van Rhijm et al. [14] reported similar sensitivity and speci-
ficity of cytology for high-grade and CIS lesions in an
inpatient setting. Haase and Harving [15] and Swietek et al.
[16] also found a close correlation between positive cytology
and CIS, and concluded that office-based white-light cystos-
copy with urinary cytology may be sufficient follow-up after
BCG, while biopsies should be taken only if the results are
positive. One study even suggests that urine cytology alone
may be sufficient follow-up in patients with CIS at risk of late
progression after 10 years of follow-up [17].
Urinary cytology should not be used as the sole method
for evaluation of treatment. In cases of malignant cells in
urine, biopsies are essential to determine possible disease
progression which may require more radical treatment [5].
In both procedures, all biopsies contained lamina propria,
allowing a diagnosis of invasive disease. If invasive disease is
diagnosed the patient should undergo resection of the
biopsy area in the OT.
EAU guidelines recommend that photodynamic-guided
biopsies following BCG treatment should be carried out
3–6 months after treatment. In Denmark, patients have
photodynamic-guided biopsies after 6 weeks to assess early
treatment response and to allow for rapid decisions on sub-
sequent treatment; in the present study, three patients were
referred for cystectomy. It has been claimed that photo-
dynamic-guided cystoscopy within 3 months of BCG instilla-
tion is difficult owing to false-positive fluorescence and
inflamed tissue confounding the visualization of CIS [18,19].
In an attempt to standardize false-positive fluorescence, only
patients who had had a full course of six weekly treatments
of BCG were included in the study. The pathologists did not
observe significant tissue inflammation and false-positive
fluorescence was not a problem during cystoscopy. The num-
ber of cases where there were insufficient biopsies for histo-
pathological diagnosis was low and similar in the two
settings.
False-positive fluorescence was observed and evaluated
by Ray et al. in their inpatient study on photodynamic-
guided biopsies following BCG instillations [20]. Although
false-positive rates were relatively high for both blue (63%)
and white (72%) light, the authors concluded that blue-light
cystoscopy was still valuable if urine cytology was positive.
Evaluation of the specificity and sensitivity of the individual
photodynamic-guided bladder biopsy has been reported pre-
viously and was therefore not the topic of this project
[21,22]. The outpatient procedure is challenged by patient
compliance, biopsy technique, confounding autofluorescence
from urine during PDD [23] and the limited possibility of
removing blood and urine by bladder irrigation through the
small, flexible cystoscopes during the procedure. This entire
procedure has not previously been evaluated and reported.
The limitation of this study is that biopsies were taken
about 3 months earlier than recommended by the EAU [4],
which may limit comparison of the results with other studies.
However, early biopsies resulted in an earlier diagnosis and
subsequent referral for radical cystectomy of three study
patients with high-grade tumour at the time of biopsy, which
may have a beneficial influence on the course of the disease.
The endoscopy time used for the PDD cystoscopy proced-
ure, including biopsies, was the same in both settings. Owing
to the requirement for general anaesthesia in the OT, patient
stay was longer, and one-third of patients stayed overnight.
The OPD procedure where the patients went home immedi-
ately after the biopsy procedure was significantly more con-
venient for patients. Staff requirements were also
considerably lower. Treatment in the OT requires an anaes-
thetist, a nurse anaesthetist, a urologist, a scrub nurse and an
assistant on the floor, as well as urology ward staff, while the
OPD requires only a nurse and a doctor. The office-based
procedure is therefore highly cost-effective and not associ-
ated with an increase in adverse events. With a pain VAS
score of 1.5 and a 27% reduction in symptom score, the
well-being of the OPD patient is not at risk.
In conclusion, photodynamic-guided diagnosis using flex-
ible cystoscopy may be an alternative in the diagnosis of CIS
to conventional inpatient photodynamic-guided cystoscopy
in sedated patients following a full course of BCG therapy.
The outpatient procedure which uses flexible cystoscopy is
safe and well tolerated, has less impact on patient QoL and
is cost-effective compared to inpatient procedures. In add-
ition, this study supports the practice that voided urinary
cytology is valuable as a monitoring tool for CIS.
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